Результаты поиска

Molecular Inhibitors of Growth Signals

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Conservative non-surgical management in medication related osteonecrosis of the jaw: A retrospective study.

OBJECTIVES: To date, the best treatment for Medication Related Osteonecrosis of the jaw (MRONJ) is controversial. Recent studies suggest different therapies, considering the stage of MRONJ; however, sometimes patients, although with remarkable extension of disease, cannot undergo surgery. The purpose of present preliminary study was to evaluate the efficacy of conservative non-surgical treatment of MRONJ lesions in a cohort of patients ineligible for surgery or refusing any surgical treatment for stage II and III of MRONJ. MATERIALS AND METHODS: Patients with MRONJ (staging II or III) ineligi

Совпадение в полном тексте источника
… To date, two main categories of drugs associated MRONJs are recognized, acting differently to bone metabolism: antiresorptive drugs (Bisphosphonates and Denosumab) and Antiangiogenic (eg Vascular Endothelial Growth Factor inhibitors such as Bevacizumab, Tyrosine Kinase inhibitors such as Sunitinib and …

Keyword Index for Volume 108

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… squamous cell carcinoma 638 Src 1143 SRC3 2039 stable disease 1021 stage III colon cancer 1238 staging 527, 1195 STAT3 653 statins 715 stem cell 1765 stem-like cell 2516 stereology 2116 steroid sulphatase 1415 stress reactions 1012 stromal resistance 1 study population 699 sulindac 512 sunitinib …

The challenge of chemotherapy-related cognitive impairment: assessing and managing cognitive decline after cancer treatment.

Chemotherapy-related cognitive impairment (CRCI) refers to a decline in cognitive function in patients during and after cancer treatment and is mainly associated with the use of cytotoxic chemotherapy (CT). As CT is still an essential component in the treatment of many cancers and taking into account the fact that cancer survival rates are increasing, CRCI may negatively impact the quality of life and working capacity of a growing number of individuals, especially those treated with curative intent in conditions such as breast cancer. There is still a need to address several issues related to

Совпадение в полном тексте источника
… In patients with metastatic renal carcinoma and gastrointestinal stromal tumour being treated with sunitinib or sorafenib, there was a worse performance in neurocognitive tests with a more significant impact on executive functions, learning and memory [ 78 ]. … Impairment of cognitive functioning during sunitinib or sorafenib treatment in cancer patients: a cross-sectional study. BMC Cancer. 2014;14:219. doi: 10.1186/1471-2407-14-219. 79. Shaw AT, Bauer TM, Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer. …

Were economic evaluations well reported for the newly listed oncology drugs in China's national reimbursement drug list.

PurposeTo assess the reporting quality of published economic evaluations of the negotiated oncology drugs listed for China's 2020 National Reimbursement Drug List (NRDL).MethodsA comprehensive search was conducted to identify economic evaluation studies of negotiated oncology drugs listed in China's 2020 NRDL using the PubMed/MEDLINE, Embase, Web of Science, CNKI, SinoMed, and WanFang Database up to March 31, 2021. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) checklist scored the reporting quality between 0 and 100. A linear regression analysis was employed to exami

Совпадение в полном тексте источника
… Cost-effectiveness of sequential therapies of sunitinib and sorafenib in metastatic ï¼²enal cell carcinoma. Chin J Drug Evaluation. 2013;30(3):178–83. 91. Huaiyong Y, Long Y, Youwei X, Xuan W. Pharmacoeconomic evaluation of sunitinib for the treatment of metastatic renal cell carcinoma. …

The Role of the Immune Response in the Development of Medication-Related Osteonecrosis of the Jaw.

Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious adverse drug effect. There are multiple hypotheses to explain the development of MRONJ. Reduced bone remodeling and infection or inflammation are considered central to the pathogenesis of MRONJ. In recent years, increasing evidence has shown that bisphosphonates (BPs)-mediated immunity dysfunction is associated with the pathophysiology of MRONJ. In a healthy state, mucosal immunity provides the first line of protection against pathogens and oral mucosal immune cells defense against potentially invading pathogens by media

Совпадение в полном тексте источника
… kinds of medication that have been reported to induce the occurrence of MRONJ, such as another anti-resorptive medication, a monoclonal antibody against the receptor activator of nuclear factor-κB (RANK) ligand (RANKL): denosumab and vascular endothelial growth factor inhibitors ( 12 ): bevacizumab, Sunitinib … Whereas, bevacizumab and Sunitinib- induced MRONJ may be associated with inhibition of angiogenesis. …

Latest advances in extracellular vesicles: from bench to bedside.

Extracellular vesicles (EVs) are small membraned vesicles and approximately 50-150 nm in diameter. Almost all of the type of cells releases the EVs and circulates in the body fluids. EVs contain multiple functional components, such as mRNAs, microRNAs (miRNAs), DNAs, and proteins, which can be transferred to the recipient cells, resulting in phenotypic changes. Recently, EV research has focused on their potential as a drug delivery vehicle and in targeted therapy against specific molecules. Moreover, some surface proteins are specific to particular diseases, and therefore, EVs also have promis

Совпадение в полном тексте источника
… The lysosome-associated membrane protein-2 (LAMP-2) is associated with endocytosis [ 107 ], knockdown of LAMP-2 improved the therapeutic effect of sunitinib in pancreatic neuroendocrine tumors [ 108 ]. … J Immunol . 2017 ; 199 : 531 – 546 . 28607115 10.4049/jimmunol.1601263 [108] Wiedmer T , Blank A , Pantasis S , et al Autophagy inhibition improves sunitinib efficacy in pancreatic neuroendocrine tumors via a lysosome-dependent mechanism . …

Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice.

The introduction of novel oncologic therapies, including targeted agents, immunotherapies, and antibody-drug conjugates, has transformed the therapeutic landscape of cancer care. This evolution has resulted in a dual clinical scenario; while survival outcomes have markedly improved, leading to a growing population of long-term cancer survivors, an increasing incidence of previously unrecognized treatment-related toxicities has emerged. Among these, cardiovascular adverse events represent some of the most prevalent and clinically significant complications observed in both conventional chemother

Совпадение в полном тексте источника
… Tyrosine Kinase Inhibitors (TKIs) Multi-targeted tyrosine kinase inhibitors (TKIs), including sunitinib, sorafenib, axitinib, vandetanib, cabozantinib, lenvatinib, pazopanib, ponatinib, and regorafenib, exert their anticancer effects in part by inhibiting key angiogenic receptors, such as vascular endothelial … Clinical data indicate that up to 47% of patients treated with sunitinib develop hypertension, approximately 28% experience left ventricular dysfunction, and about 8% progress to heart failure [ 65 ]. Sorafenib exhibits a similar, though somewhat milder, cardiotoxicity profile [ 66 ]. …

Blockage of Autophagy for Cancer Therapy: A Comprehensive Review.

The incidence and mortality of cancer are increasing, making it a leading cause of death worldwide. Conventional treatments such as surgery, radiotherapy, and chemotherapy face significant limitations due to therapeutic resistance. Autophagy, a cellular self-degradation mechanism, plays a crucial role in cancer development, drug resistance, and treatment. This review investigates the potential of autophagy inhibition as a therapeutic strategy for cancer. A systematic search was conducted on Embase, PubMed, and Google Scholar databases from 1967 to 2024 to identify studies on autophagy inhibito

Clinical outcomes of chemotherapy in cancer patients with different ethnicities.

BackgroundChoosing the most effective chemotherapeutic agent with safest side effect profile is a common challenge in cancer treatment. Although there are standardized chemotherapy protocols in place, protocol changes made after extensive clinical trials demonstrate significant improvement in the efficacy and tolerability of certain drugs. The pharmacokinetics, pharmacodynamics, and tolerance of anti-cancer medications are all highly individualized. A driving force behind these differences lies within a person's genetic makeup.Recent findingsPharmacogenomics, the study of how an individual's g

Совпадение в полном тексте источника
… efflux out of the target cells are crucial factors in TKI drug action and delivery. 9 Cytochrome‐P450 (CYP) enzymes are primarily responsible for metabolizing TKI by phase I and UDP‐glucuronosyltransferases (UGTs) by phase II reactions. 142 The enzyme CYP3A4 is principally responsible for metabolism of sunitinib …

A new therapeutic approach in Gorham-Stout disease: a case report.

BackgroundGorham-Stout disease is a rare condition of unknown prevalence and unknown exact cause. Its pathogenesis is based on enhanced osteoclastic activity leading to bone resorption and bone replacement by distended lymphatic vessels. Because of its rarity and a various range of symptoms the disease may give, diagnosis is challenging and a strong index of suspicion is required. Although it is a benign condition, the prognosis may be unpredictable. The treatment options suggested so far are limited, and every case should be provided with the best individual approach. Herein, we present a cas

Совпадение в полном тексте источника
… Table 1 Medications used in Gorham–Stout disease List of medications used in Gorham–Stout disease Bisphosphonates | Cyclophosphamide Calcium | Vincristine Vitamin D | Sunitinib Corticosteroids | Taxol Interferon α-2b | Hydroxychloroquine Octreotide | Acetazolamide Bevacizumab | Calcitonin Propranolol …

Epidemiology of multiple myeloma in Poland in the years 2008-2017.

IntroductionMultiple myeloma is the third most common blood cancer in Europe and accounts for approx. 10-15% of these cancers. The objective of this study was to determine the incidence, prevalence, mortality and survival in multiple myeloma (ICD code: C90.0) patients in Poland in the years 2008-2017.Material and methodsThe analysis used the data on healthcare services provided to patients with multiple myeloma defined with the ICD-10 (International Statistical Classification of Diseases and Related Health Problems) code C90.0 and reported by healthcare entities to the National Health Fund (NF

Совпадение в полном тексте источника
… Real-world evidence of patient outcome following treatment of advanced gastrointestinal stromal tumor (gist) with imatinib, sunitinib, and sorafenib in publicly funded health care in Poland. Med Sci Monit 2019; 25: 3846-53. 20. Niklas A, Flotyńska A, Puch-Walczak A, et al. …

Cardiotoxicity in people undergoing cancer treatment - the role of the oncology nurse.

Cardiotoxicity is a significant complication of cancer treatment, and this review describes the cardiovascular risks associated with various therapies and emphasizes the crucial role of oncology nurses in managing these risks. Many cancer treatments, including cytotoxic therapies, radiation, targeted therapies, and immune-modulatory drugs, have been shown to increase the likelihood of cardiovascular toxicity, leading to conditions such as acute coronary syndrome, heart failure, and atrial fibrillation. Guidelines are now available to reduce treatment-related cardiovascular toxicity (CTR-CVT) a

Совпадение в полном тексте источника
… Monoclonal antibodies and small molecule tyrosine kinase inhibitors (for example: gefitinib, erlotinib, sorafenib, sunitinib, and dasatinib) have also been associated with CTR-CVT. …

Analysis of SIRT1 Gene SNPs and Clinical Characteristics in Medication-Related Osteonecrosis of the Jaw.

Certain genetic factors, including single-nucleotide polymorphisms (SNPs) in the SIRT1 gene, have been linked to medication-related osteonecrosis of the jaw (MRONJ). This study examined four SNPs in the SIRT1 gene and implemented multivariate statistical analysis to analyze genetic and clinical factors in MRONJ patients. Genomic DNA was isolated from peripheral blood samples of 63 patients of European origin treated for MRONJ, and four SNP genotypes in the gene encoding the SIRT-1 protein were determined by Sanger sequencing. The allele frequencies measured in the MRONJ population were compare

Совпадение в полном тексте источника
… These agents include denosumab, tyrosine kinase inhibitors (e.g., sunitinib, sorafenib or cabozantinib), everolimus (an mTOR-inhibitor), tocilizumab (an interleukin-6 receptor inhibitor) and anti-vascular endothelial growth factor (anti-VEGF) monoclonal antibodies, such as bevacizumab [ 5 , 6 ]. …

Ocular complications with the use of radium-223: a case series.

BackgroundRadium-223 is used for the treatment of osseous metastases in castrate-resistant prostate cancer, and has been shown to increase time to the first skeletal-related event, reduce the rate of hospitalization, and improve quality of life. It is well tolerated, with hematologic toxicity as the main adverse event. Thus far, no ocular complication has been reported in the literature after initial administration of radium-223 with a single case reported of ocular complications after a patient's second course of radium-223.Case presentationsWe present three cases of ocular complications afte

Совпадение в полном тексте источника
… A relationship between PRES and cancer medications including cytotoxic chemotherapeutics and newer agents that target VEGF such as bevacizumab, sunitinib, and pazopanib has been observed [ 27 , 28 ]. …

Bisphosphonate-related osteonecrosis of the jaw: specificities.

Bisphosphonate-related osteonecrosis of the jaws (BRONJ) is a severe complication that has recently emerged in patients treated with intravenous bisphosphonates for malignant diseases. This complication usually presents after a minor local trauma during a dental treatment. Several etiopathogenic mechanisms of this pathological condition have been proposed, but no model can explain all morphological changes observed at the macroscopic and microscopic level. BRONJ is likely to be related to direct toxicity in the bone and soft tissue cells, due to nitrogen-containing bisphosphonates. This review

Совпадение в полном тексте источника
… Evidence in the medical and dental literature reveals cases of ONJ associated with the use of drugs other than bisphosphonates, including denosumab, a human monoclonal antibody that inhibits the receptor activator of RANKL and antiangiogenic drugs tested in advanced cancer cases, such as bevacizumab, sunitinib …

A novel approach to enhance glioblastoma multiforme treatment efficacy: non-coding RNA targeted therapy and adjuvant approaches.

BackgroundGlioblastoma multiforme (GBM) is a lethal brain tumor. With the current gold standard chemotherapy treatment, temozolomide (TMZ), many patients do not survive beyond one year. While the urgency of researching novel treatments is understandable, the prohibitively high costs and the prolonged duration of research and clinical trials significantly delay the availability of medical advancements to the general public. This highlights the urgent need for adjuvant therapies to enhance treatment effectiveness.Main bodyRecent research has suggested the potential of repurposing FDA-approved dr

Совпадение в полном тексте источника
… Aspirin combination therapy with TMZ, bevacizumab, and sunitinib has also inhibited tumor formation by blocking angiogenesis and increasing cell sensitivity in human primary GBMM-endothelial cells which originated from five GBM patients after surgical resection at the Neurosurgery Unit of Fondazione … Aspirin affects tumor angiogenesis and sensitizes human glioblastoma endothelial cells to temozolomide, bevacizumab, and sunitinib, impairing vascular endothelial growth factor-related signaling. World Neurosurg. 2018;120:e380–91. 101. …

Cardiovascular Biomarkers in Cardio-Oncology: Antineoplastic Drug Cardiotoxicity and Beyond.

Serum biomarkers represent a reproducible, sensitive, minimally invasive and inexpensive method to explore possible adverse cardiovascular effects of antineoplastic treatments. They are useful tools in risk stratification, the early detection of cardiotoxicity and the follow-up and prognostic assessment of cancer patients. In this literature review, we aim at describing the current state of knowledge on the meaning and the usefulness of cardiovascular biomarkers in patients with cancer; analyzing the intricate relationship between cancer and cardiovascular disease (especially HF) and how this

Совпадение в полном тексте источника
… Jensen et al. demonstrated significant decreases in docosahexaenoic acid, arachidonic acid/eicosatetraenoic acid, o-phosphocolamine and 6-hydroxynicotinic acid in the hearts of mice treated with sunitinib [ 143 ], along with alterations in taurine/hypotaurine metabolism, after sorafenib treatment [ 144 … Non-Targeted Metabolomics Analysis of the Effects of Tyrosine Kinase Inhibitors Sunitinib and Erlotinib on Heart, Muscle, Liver and Serum Metabolism In Vivo Metabolites 2017 7 31 10.3390/metabo7030031 28640223 PMC5618316 144. Jensen B.C. Parry T.L. Huang W. Beak J.Y. Ilaiwy A. Bain J.R. …

The Advent of Molecular Targeted Therapies Against Cancer. Toward Multi-Targeting Drugs Through Materials Engineering: A Possible Future Scenario.

The authors, actively engaged in the development of mesoporous silica-based solutions, initially for modified drug release, later for the smart administration of conventional chemotherapeutic cytotoxic drugs, present the evolution of the concept of targeted therapy across different disciplines. They also discuss the diverse therapeutic needs and related challenges (adverse drug effects) that have unfolded over the last 30 years. Nanomedicine potentialities, mainly against cancers, that have emerged globally during the intense research activity of the last few decades, are critically discussed.

Совпадение в полном тексте источника
… untreated advanced renal‐cell carcinoma | Nivolumab plus Cabozantinib | median PFS 16.6 months; (95% C.I. 12.5–24.9); Objective response 55.7% (95% C.I. 50.1–61.2) | Randomized, open‐label trial, that patients received either nivolumab (240 mg every 2 weeks) plus cabozantinib (40 mg once daily) or sunitinib … (50 mg once daily for 4 weeks of each 6‐week cycle) | [ 117 ] Sunitinib | Median PFS 8.3 months; (95% C.I. 7–9.7); Objective response 27.1% (95% C.I. 22.4–32.3) Cabozantinib, a tyrosine kinase inhibitor (TKI), effectively targets VEGF receptors (VEGFRs), MET, AXL, and other receptor tyrosine kinases …

Venous and Arterial Thromboembolism in Patients With Cancer: JACC: CardioOncology State-of-the-Art Review.

Venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, represents a major cause of morbidity and mortality in patients with cancer. Arterial thromboembolism, including myocardial infarction and stroke, is also prevalent. Risk differs in subgroups, with higher rates observed in specific cancers including pancreas, stomach, and multiple myeloma. Thromboprophylaxis is recommended for most patients with active cancer hospitalized for medical illnesses and after major cancer surgery. Outpatient thromboprophylaxis is not routinely recommended, but emerging data suggest

Совпадение в полном тексте источника
… Antiangiogenetic drugs, such as bevacizumab, a monoclonal antibody against vascular endothelial growth factor receptor (VEGFR), increase the risk for ATE ( 41 ), as do the multitargeted agents sorafenib and sunitinib, although their precise impact on VTE is not clear ( 42 ). … Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol. 2010;28:2280–2285. doi: 10.1200/JCO.2009.27.2757. 43. Roopkumar J., Swaidani S., Kim A.S. …